Cortagen Research Overview (also known as Ala-Glu-Asp-Arg, Cerebral cortex bioregulator, Brain tetrapeptide bioregulator)
A tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Khavinson's group targeting gene expression in cerebral cortex neurons. Research interest includes age-related cognitive decline, neuroprotection, and neurodegeneration.
What Is Cortagen?
Cortagen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology as part of the systematic Khavinson bioregulator series. Cortagen is designed to selectively interact with gene regulatory elements in neurons and glial cells of the cerebral cortex, with the aim of modulating transcription pathways associated with neuronal survival, synaptic plasticity, and age-related neurodegeneration.
Within the Khavinson framework, each tetrapeptide carries a unique amino acid sequence that confers DNA-binding specificity for a particular tissue type. Cortagen’s sequence Ala-Glu-Asp-Arg corresponds to the regulatory peptide fraction derived from cortical brain tissue extracts. It is distinct from Pinealon (which targets the pineal gland) and from nootropic peptides like Semax and Selank — functioning instead as a slow-acting geroprotective and neuroprotective bioregulator intended for multi-course use.
Cortagen is available for research use only and is not approved as a therapeutic drug in the United States or European Union.
Mechanism of Action
Cortagen’s proposed mechanism involves sequence-specific interaction between the tetrapeptide (Ala-Glu-Asp-Arg) and complementary DNA promoter regions in cortical neurons and glia. Khavinson’s group demonstrated that short peptide bioregulators of this class bind to di- and trinucleotide sequences in a manner consistent with minor groove DNA binding, altering chromatin accessibility and transcription factor recruitment at target gene loci.
In cortical tissue, Cortagen has been proposed to modulate expression of genes governing: (1) anti-apoptotic pathways (Bcl-2 family upregulation); (2) BDNF and NGF signaling, supporting dendritic arborization and synaptic maintenance; (3) antioxidant enzymes including SOD and catalase; and (4) mitochondrial biogenesis regulators that support neuronal energy homeostasis.
Unlike fast-acting neuroactive peptides that cross the blood-brain barrier acutely, Cortagen is injected peripherally (SubQ) and is thought to act through peripheral regulatory cascades rather than direct CNS penetration. Its effects are described as cumulative across multiple treatment courses.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Neuroprotection Research
Age-Related Cognitive Decline
Khavinson studies report improvements in memory consolidation, attention, and processing speed in elderly subjects over 20–day Cortagen courses, with effects cumulative over 2–3 course sequences.
Neurodegeneration Models
In rodent models of accelerated aging, Cortagen was associated with preservation of cortical neuron density and reduced lipofuscin accumulation across Khavinson institutional studies.
Post-Stroke Recovery
Institutional reports from Russian clinical contexts describe accelerated cognitive and motor recovery in post-stroke rehabilitation when Cortagen was included in multi-peptide protocols.
Neurological Restoration
TBI Recovery Research
Limited case data suggest potential benefit in supporting cortical plasticity during post-TBI rehabilitation; no controlled trials available in Western literature.
Stress Resilience & HPA Regulation
Modulation of cortical gene expression pathways linked to HPA axis regulation and stress response observed in preclinical aging models.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg | Once daily | SubQ |
| Conservative Aging Protocol | 1 mg | Once daily | SubQ |
Peptide Interactions
Both are Khavinson CNS tetrapeptide bioregulators (Cortagen: cerebral cortex; Pinealon: pineal gland). Stacking provides broader CNS regulatory coverage.
Semax acts acutely on BDNF/ACTH pathways; Cortagen acts slowly via transcriptional modulation. May provide short- and long-term neuroprotective coverage.
Selank modulates anxiety and immune balance via GABAergic and TGF-β pathways; commonly paired with Cortagen in Russian nootropic-bioregulator research stacks.
Epitalon targets telomerase activation and circadian regulation; combined with Cortagen the pairing addresses aging across cortical and neuroendocrine axes.
Dihexa is a potent HGF/MET agonist with strong synaptogenic activity. Combining with cortagen’s transcriptional modulation may produce additive long-term cognitive support.
Reported Research Timeline
01Course 1 (Days 1–20): Peripheral regulatory cascade initiated; acute cognitive enhancement should not be expected. Cortagen operates on a slow transcriptional timeline.
02Course 2–3 (Month 3–6): Sustained attention and working memory improvements begin to emerge on cognitive testing; reduced frequency of stress-related cognitive lapses reported.
03Course 4+ (Month 6–12+): Cumulative neuroprotective benefit; optimized through annual protocol. Primary value is preservation of cortical function over time, not acute enhancement.
Side effects (reported in cited studies): usually minimal; no significant adverse effects in Khavinson institutional data
Most common (reported in cited studies): mild injection-site erythema; transient soreness at SubQ site
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated in Khavinson institutional studies. No serious adverse effects reported in published research.
Not a substitute for neurological care. Cortagen is an RUO compound. Subjects with neurological conditions should not replace physician-supervised care with Cortagen.
Interactions with CNS-active agents: No interaction data available. Use caution when combining with other neuroactive peptides, nootropics, or pharmaceuticals that modulate neurotransmission.
Injection-site reactions possible. Rotate SubQ sites with each injection.
Storage: Lyophilized at 2–8°C; reconstituted solution stable up to 30 days at 2–8°C; protect from light.
RUO only. Procure from vendors providing third-party CoA with HPLC purity and mass-spec sequence confirmation.
Seek Medical Attention If:
Cardiovascular symptoms: chest pain, palpitations, or shortness of breath
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Always consult a licensed physician before and during use
Quality Indicators
Verified Marker
Lyophilized Powder Appearance
White to off-white lyophilized powder. Discard vials with discoloration, aggregation, or signs of moisture.
Verified Marker
Certificate of Analysis (CoA)
Third-party HPLC purity ≥98%; mass spectrometry confirmation of Ala-Glu-Asp-Arg sequence; LAL endotoxin test ≤2 EU/mg.
Verified Marker
Sterility Testing
Vendor-provided USP-compliant sterility results for injectable-grade vials.
Expected
Reconstituted Solution Clarity
Clear and colorless after reconstitution with BAC water or sterile saline. Turbidity or particulates indicate degradation.
Expected
Vial Seals
Intact crimp cap and rubber stopper. Reject compromised packaging.
Red Flag
Pre-mixed liquid formats
Injectable bioregulators are lyophilized; a vendor supplying pre-mixed liquid Cortagen suggests inadequate manufacturing controls.
Research Citations
- Gerontological Aspects of Genome Peptide Regulation
Khavinson VKh, Malinin VV. Karger: Basel, 2005. - Peptide regulation of gene expression in the human cerebral cortex neurons
Khavinson VKh, Linkova NS, Kvetnoy IM, et al. Bulletin of Experimental Biology and Medicine. 2012;154(1):88–91. - Effect of bioregulatory peptides on biological age in elderly subjects
Khavinson VKh, Anisimov SV, Zavarzina NY, et al. Neuroendocrinology Letters. 2001. - Peptide AEDR alters expression of genes regulating cortical neuron differentiation
Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. Biochemistry (Moscow). 2020;85(12).
Research Focus
Neuroprotection, Cognitive aging, Neurodegeneration, Cerebral cortex, Khavinson bioregulator
Frequently Asked Questions
What should researchers watch for with Cortagen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cortagen?
Course 1 (Days 1–20): Peripheral regulatory cascade initiated; acute cognitive enhancement should not be expected. Cortagen operates on a slow transcriptional timeline.
How is Cortagen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →